PPP De Novo - ParkinsonOpMaat

html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

Study Parkinson Op Maat De Novo

PPP De Novo

Because of the success of the PPP, a collaboration between the Radboudumc and the pharmaceutical company UCB (Union Chimique Belge) has started. This collaboration has led to a new study: PPP De Novo. read more (in Dutch)

About the study

This study differs from the PPP-study in that the focus is on collecting research data from people with parkinson's who are not yet taking parkinson's medication.

lees meer

About the study

Because of the success of the PPP, a collaboration between the Radboudumc and the pharmaceutical company UCB (Union Chimique Belge) has started. This collaboration has led to a new study: PPP De Novo. This study differs from the PPP-study in that the focus is on collecting research data from people with parkinson's who are not yet taking parkinson's medication. The survey data will be used to develop a new measure to measure Parkinson's disease in a reliable and objective way.

This website uses cookies. Read more about cookies.